relies on faulty comparisons and fuzzy math. News reports and opinion columns often cite misleading statistics from 340B opponents.
340B critics obfuscate the true nature of the 340B program by referencing its federal origins. The tact is meant to mislead Americans into thinking they foot the bill for 340B. But the program is not analogous to Medicare and Medicaid. Drug companies resort to drug pricing gimmicks to exaggerate the size of 340B purchases. Instead of using the actual price, drug makers use their list prices to measure 340B’s relative size. By that metric, 340B sales in 2021 registeredBut think of drug company list prices as the sticker price for a new car. Car dealerships and drug companies can set their prices however they want. Consumers only care what they pay for cars, and in this case, their medications.
According to the pharmaceutical industry, the “explosive" growth of 340B means they will have to make up for supposed lost revenue elsewhere. In reality, drug companies are more concerned that they cannot charge nonprofit providers arbitrary list prices.